Skip to main content
Year archive

MorphoSys AG — 2017 filings

All 79 regulatory filings released by MorphoSys AG (MOR) in 2017, sourced directly from the official regulator.

79 Filings
2017 Period
2017 filings (79)
Filing Released Lang
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-12-29 English
MorphoSys to Present at Upcoming Investor Conferences
Regulatory Filings
2017-12-14 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-12-14 English
Report Publication Announcement 2017
Report Publication Announcement
2017-12-11 English
Report Publication Announcement 2017
Report Publication Announcement
2017-12-11 English
MorphoSys AG: Corporate Calendar 2018
Report Publication Announcement
2017-12-11 English
MorphoSys Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference (news with additional features)
Earnings Release FY 2017
2017-12-11 English
MorphoSys to Host Investor & Analyst Call on December 12, 2017 about Data on MOR208 presented at the 2017 ASH Annual Meeting
Report Publication Announcement
2017-12-05 English
MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada (news with additional features)
Regulatory Filings
2017-12-05 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-11-30 English
MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab (news with additional features)
Earnings Release FY 2017
2017-11-30 English
Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
Earnings Release FY 2017
2017-11-30 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-11-23 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-11-23 English
MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis (news with additional features)
Regulatory Filings
2017-11-23 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-11-14 English
MorphoSys Announces Third Quarter 2017 Results (news with additional features)
Earnings Release Q3 2017
2017-11-07 English
Q3 statement / Q3 financial report 2017
Interim / Quarterly Report 9M 2017
2017-11-07 German
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017 (news with additional features)
Regulatory Filings
2017-11-02 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-10-30 English
Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer (news with additional features)
Board/Management Information
2017-10-30 English
MorphoSys to Host Q3 2017 Conference Call on November 7, 2017
Report Publication Announcement
2017-10-26 English
MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL (news with additional features)
Regulatory Filings
2017-10-23 English
Adhoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
Regulatory Filings
2017-10-23 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-10-04 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-09-29 English
MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients (news with additional features)
Legal Proceedings Report
2017-09-27 English
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with TremfyaTM (Guselkumab) in Psoriatic Arthritis (news with additional features)
Legal Proceedings Report
2017-09-21 English
MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya(TM) (Guselkumab) Recommending Approval in Europe (news with additional features)
Regulatory Filings
2017-09-18 English
MorphoSys Presents Vision for Growth at its Capital Markets Day (news with additional features)
Investor Presentation
2017-09-05 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-08-31 English
MorphoSys to Present at Upcoming Investor Conferences
Report Publication Announcement
2017-08-10 English
MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 (news with additional features)
Earnings Release Q2 2017
2017-08-03 English
Half-yearly financial report 2017
Interim / Quarterly Report H2 2017
2017-08-03 German
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-07-31 English
MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma (news with additional features)
Legal Proceedings Report
2017-07-21 English
Adhoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
Regulatory Filings
2017-07-21 English
Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Regulatory Filings
2017-07-13 English
MorphoSys to Host Q2 2017 Conference Call on August 3, 2017
Report Publication Announcement
2017-07-13 English
MorphoSys Celebrates 25th Anniversary (news with additional features)
Regulatory Filings
2017-07-06 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-06-30 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-06-21 English
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at ASCO 2017 (news with additional features)
Regulatory Filings
2017-06-05 English
MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL (news with additional features)
Regulatory Filings
2017-06-02 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-05-31 English
MorphoSys Announces That Its Licensee Janssen Reported Updates on the Development of Guselkumab (news with additional features)
Regulatory Filings
2017-05-24 English
MorphoSys to Present at Three Upcoming Conferences (news with additional features)
Regulatory Filings
2017-05-24 English
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers (news with additional features)
Regulatory Filings
2017-05-19 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-05-18 English
MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017 (news with additional features)
Regulatory Filings
2017-05-18 English
MorphoSys AG Reports Outcome of Annual General Meeting 2017 (news with additional features)
AGM Information
2017-05-17 English
MorphoSys AG Reports Solid First Quarter 2017 (news with additional features)
Earnings Release Q1 2017
2017-05-03 English
Q1 statement / Q1 financial report 2017
Interim / Quarterly Report Q1 2017
2017-05-03 German
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-05-02 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-04-28 English
MorphoSys to Host Q1 2017 Conference Call on May 3, 2017 (news with additional features)
Report Publication Announcement
2017-04-24 English
MorphoSys to Present at Upcoming Conferences (news with additional features)
Report Publication Announcement
2017-04-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-04-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-04-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-04-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-04-05 English
MorphoSys Nominates New Candidate for Supervisory Board (news with additional features)
Board/Management Information
2017-04-03 English
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 17.05.2017 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2017-03-30 German
DGAP-DD: MorphoSys AG english
Director's Dealing
2017-03-29 English
Annual financial report 2016
Annual Report FY 2016
2017-03-27 German
MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO (news with additional features)
Board/Management Information
2017-03-23 English
MorphoSys AG Presents Strong Results for Fiscal Year 2016 (news with additional features)
Earnings Release FY 2016
2017-03-09 English
MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease (news with additional features)
Legal Proceedings Report
2017-03-06 English
MorphoSys Announces That Its Licensee Janssen Has Reported New Data From Two Phase 3 Studies of Guselkumab in Plaque Psoriasis (news with additional features)
Legal Proceedings Report
2017-03-03 English
Invitation to Year-End Results 2016 Conference Call
Report Publication Announcement
2017-03-02 English
MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Regulatory Filings
2017-02-21 English
District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit
Legal Proceedings Report
2017-02-15 English
MorphoSys to Present at Upcoming Conference
Regulatory Filings
2017-02-10 English
Report Publication Announcement 2017
Report Publication Announcement
2017-02-01 English
Report Publication Announcement 2017
Report Publication Announcement
2017-02-01 English
MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes
Regulatory Filings
2017-01-12 English
Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG
Board/Management Information
2017-01-05 English
MorphoSys to Present at Upcoming Investor Conferences
Regulatory Filings
2017-01-03 English